deltatrials
Recruiting INTERVENTIONAL NCT07033481

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)

Sponsor: CervoMed, Inc

Conditions Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Interventions Neflamapimod Placebo
Updated 3 times since 2025 Last updated: Apr 20, 2026 Started: Oct 2, 2025 Primary completion: Sep 1, 2026 Completion: Oct 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07033481, this observational or N/A phase trial focuses on Nonfluent Variant Primary Progressive Aphasia (nfvPPA) and remains actively recruiting participants. Sponsored by CervoMed, Inc, it has been updated 3 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshotRecruiting~Sep 2025 – ~Apr 2026 · 8 months · monthly snapshotRecruitingApr 23, 2026 – present · 3 months · daily APIRecruiting

Change History

3 versions recorded

  1. Apr 23, 2026 — Present [daily]

    Recruiting

    Phase: PHASE2 → None

  2. Sep 2025 — Apr 2026 [monthly]

    Recruiting PHASE2

  3. Jul 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.

Contact Information

Sponsor contact:
  • CervoMed, Inc
  • EIP Pharma Inc
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations